# BioNTech SE Shifts Focus

> BioNTech SE pivots from pandemic vaccines to oncology with $19B cash and 33 trials.
- Title: BioNTech SE Shifts Focus · Seekingalpha | Shortify
- Summary: BioNTech SE pivots from pandemic vaccines to oncology with $19B cash and 33 trials. BioNTech SE is shifting from COVID-19 vaccines to oncology with $19B cash…
- Keywords: biontech, oncology, phase 2/3 trials, cash reserves, pivotal data, money, business, Shifts, Focus, Seekingalpha
- Source: Seekingalpha — https://seekingalpha.com/article/4951846-biontech-se-moving-past-covid
- Author: Bret Jensen
- Published: 2026-10-04T13:44:11+00:00
- Read time: 1 min
- Topics: biontech, se, oncology, phase 2/3 trials, cash reserves, pivotal data, money, business
## BioNTech SE
BioNTech SE is pivoting from a COVID-19 vaccine windfall to a robust oncology pipeline.
## 33 Phase 2/3 Trials
BioNTech SE has 33 Phase 2/3 trials in its oncology pipeline.
## $19B Cash Reserves
BioNTech SE holds $19B in cash reserves for future oncology development.
## Pumitamig Development
BioNTech SE's pumitamig, a PD-L1xVEGF bispecific, is in a crowded oncology space.
## Pivotal Data Timeline
Pivotal data for pumitamig is expected post-2028 in the oncology space.
## Profitability Timeline
BioNTech SE will not become profitable until 2031 despite strong cash reserves.
## Key takeaway

BioNTech SE is shifting from COVID-19 vaccines to oncology with $19B cash and 33 Phase 2/3 trials.